GALTON clinical trial for untreated CLL

[Guest guest]

This is an open-label, 2-arm, nonrandomized, multicenter, Phase Ib study to

investigate the safety and efficacy of GA101 administered in combination with FC

or bendamustine, in patients with previously untreated CD20-positive B-CLL.

GA-101, a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb.

The next generation of Rituxan...

http://clinicaltrials.gov/ct2/show/NCT01300247

[Guest guest]

Doesn't show locations. Any clue?

Thanks

Lynn

>

> This is an open-label, 2-arm, nonrandomized, multicenter, Phase Ib study to

investigate the safety and efficacy of GA101 administered in combination with FC

or bendamustine, in patients with previously untreated CD20-positive B-CLL.

>

> GA-101, a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb.

>

> The next generation of Rituxan...

>

>

> http://clinicaltrials.gov/ct2/show/NCT01300247

>

[Guest guest]

Hi, Apparently it's not yet recruiting ... but you

might call to inquire: 888-662-6728

Karl